A Phase 4, Randomized, Double-Blind, Placebo-Controlled, Post-Marketing Study to Evaluate the Efficacy and Safety of an Omicron JN.1 Subvariant SARS-CoV-2 rS Vaccine Adjuvanted With Matrix-M® in Adults 50 to < 65 Years of Age Without High Risk Conditions for Severe COVID-19

ingentiumby ingentium

In Vaccines News.

A Phase 4, Randomized, Double-Blind, Placebo-Controlled, Post-Marketing Study to Evaluate the Efficacy and Safety of an Omicron JN.1 Subvariant SARS-CoV-2 rS Vaccine Adjuvanted With Matrix-M® in Adults 50 to < 65 Years of Age Without High Risk Conditions for Severe COVID-19

Publication date: Jul 17, 2025

This is a Phase 4, post-market US study, evaluating the efficacy and safety of a single dose of the NVX-CoV2705 Omicron JN. 1 COVID-19 vaccine. Approximately 6,500 healthy adults aged 50 to under 65 will be randomized to receive either the vaccine or a placebo, with follow-up for 180 days.

Concepts Keywords
Coronavirus COVID-19
Male
Myocarditis
Nanoparticle
Vaccinated

Semantics

Type Source Name
disease MESH COVID-19
disease MESH amenorrhea
disease IDO country
drug DRUGBANK Levonorgestrel
disease MESH lifestyle
disease IDO history
disease MESH infection
disease MESH allergies
disease MESH anaphylaxis
disease MESH myocarditis
disease MESH pericarditis
drug DRUGBANK Prednisone
drug DRUGBANK Tacrolimus
drug DRUGBANK Ciclosporin
disease IDO blood
disease IDO quality
disease IDO site
pathway REACTOME SARS-CoV-2 Infection

Original Article

(Visited 3 times, 1 visits today)